So you think CXR paid too much for their drug rights?I cannot think of a BP in the past that has not paid too much for a drug, or co-licensing agreement, or co-promotion contract, or process & development acquisition, or BioTech company. It's pretty common occurrence, and guess what? All those companies are still around and flourishing after the setback. Pharma companies drop or cancel formal agreements all the time if market realities turn out different than expected. Nothing new here. CXR will be fine.